Egrifta WR — Point32Health
Human immunodeficiency virus (HIV)-associated lipodystrophy
Initial criteria
- Documentation the patient has excess abdominal fat secondary to human immunodeficiency virus (HIV)-associated lipodystrophy
Approval duration
24 months